{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:12:56Z","timestamp":1791972776963,"version":"4.3.4"},"reference-count":63,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100010308","name":"Dr Heinz-Horst Deichmann Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010308","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","hpbonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["HPB"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.hpb.2018.12.014","type":"journal-article","created":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T01:29:36Z","timestamp":1549330176000},"page":"773-783","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Radioembolisation with 90Y microspheres for neuroendocrine liver metastases: an institutional case series, systematic review and meta-analysis"],"prefix":"10.1016","volume":"21","author":[{"given":"Andrea","family":"Frilling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley K.","family":"Clift","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur J.A.T.","family":"Braat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Alsafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpreet S.","family":"Wasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil","family":"Al-Nahhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Drymousis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagy","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul N.","family":"Tait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hpb.2018.12.014_bib1","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1002\/ijc.30400","article-title":"The epidemiology of metastases in neuroendocrine tumors","volume":"139","author":"Riihim\u00e4ki","year":"2016","journal-title":"Int J Canc"},{"key":"10.1016\/j.hpb.2018.12.014_bib2","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/cncr.28760","article-title":"Therapeutic strategies for neuroendocrine liver metastases","volume":"121","author":"Frilling","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.hpb.2018.12.014_bib3","first-page":"172","volume":"103","author":"Pavel","year":"2016"},{"key":"10.1016\/j.hpb.2018.12.014_bib4","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.hpb.2018.12.014_bib5","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S1470-2045(13)70362-0","article-title":"Recommendations for management of patients with neuroendocrine liver metastases","volume":"15","author":"Frilling","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hpb.2018.12.014_bib6","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1245\/s10434-010-1154-5","article-title":"Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis","volume":"17","author":"Mayo","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.hpb.2018.12.014_bib7","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1245\/s10434-017-5839-x","article-title":"Management of neuroendocrine tumor liver metastases: long-term outcomes and prognostic factors from a large prospective database","volume":"24","author":"Fairweather","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.hpb.2018.12.014_bib8","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1016\/j.suronc.2012.05.001","article-title":"Surgical resection of hepatic metastases from neuroendocrine neoplasms: a systematic review","volume":"21","author":"Saxena","year":"2012","journal-title":"Surg Oncol"},{"key":"10.1016\/j.hpb.2018.12.014_bib9","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.hpb.2018.12.014_bib10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of177Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hpb.2018.12.014_bib11","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.surg.2010.09.014","article-title":"Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up","volume":"148","author":"Akyildiz","year":"2010","journal-title":"Surgery"},{"key":"10.1016\/j.hpb.2018.12.014_bib12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/MPA.0000000000000030","article-title":"Comparison of transarterial liver-directed therapies for low-grade metastatic neuroendocrine tumors in a single institution","volume":"43","author":"Engelman","year":"2014","journal-title":"Pancreas"},{"key":"10.1016\/j.hpb.2018.12.014_bib13","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s12020-018-1537-0","article-title":"Hepatic intra-arterial therapies in metastatic neuroendocrine tumors: lessons from clinical practice","volume":"60","author":"Grozinsky-Glasberg","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.hpb.2018.12.014_bib14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/hpb.12326","article-title":"Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference","volume":"17","author":"Kennedy","year":"2015","journal-title":"HPB"},{"key":"10.1016\/j.hpb.2018.12.014_bib15","doi-asserted-by":"crossref","first-page":"vii124","DOI":"10.1093\/annonc\/mds295","article-title":"Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Oberg","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hpb.2018.12.014_bib16","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/COC.0b013e3182005768","article-title":"Integrating radioembolization into the treatment paradigm for metastatic neuroendocrine tumors in the liver","volume":"35","author":"Kennedy","year":"2012","journal-title":"Am J Clin Oncol"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.hpb.2018.12.014_bib17","first-page":"242","article-title":"International multicenter retrospective study on the efficacy and toxicity of radioembolization in neuroendocrine tumours with yttrium-90 resin microspheres","author":"Braat","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.hpb.2018.12.014_bib18","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00428-007-0452-1","article-title":"TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system","volume":"451","author":"Rindi","year":"2007","journal-title":"Virchows Arch"},{"key":"10.1016\/j.hpb.2018.12.014_bib19","series-title":"AJCC cancer staging manual (Ed. 7)","author":"Edge","year":"2010"},{"key":"10.1016\/j.hpb.2018.12.014_bib20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.hpb.2018.12.014_bib21","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jvir.2009.05.030","article-title":"Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review","volume":"20","author":"Riaz","year":"2009","journal-title":"J\u00a0Vasc Intervent Radiol"},{"key":"10.1016\/j.hpb.2018.12.014_bib22","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.ijrobp.2008.10.005","article-title":"Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors","volume":"74","author":"Kennedy","year":"2009","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.hpb.2018.12.014_bib23","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/hep.29207","article-title":"Prevention and treatment of complications of selective internal radiation therapy: expert guidance and systematic review","volume":"66","author":"Sangro","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.hpb.2018.12.014_bib24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/2049-3258-72-39","article-title":"Metaprop: a Stata command to perform meta-analysis of binomial data","volume":"72","author":"Nyaga","year":"2014","journal-title":"Arch Public Health"},{"key":"10.1016\/j.hpb.2018.12.014_bib25","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s00259-015-3178-3","article-title":"Molecular response assessed by 68Ga-DOTANOC and survival after 90Y microsphere therapy in patients with liver metastases from neuroendocrine tumours","volume":"43","author":"Filippi","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.hpb.2018.12.014_bib26","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s00268-017-4324-9","article-title":"Radioembolization versus bland embolization for hepatic metastases from small intestinal neuroendocrine tumors: short-term results of a randomized clinical trial","volume":"42","author":"Elf","year":"2018","journal-title":"World J Surg"},{"key":"10.1016\/j.hpb.2018.12.014_bib27","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/j.jvir.2017.07.008","article-title":"Tumor dose response in yttrium-90 resin microsphere embolization for neuroendocrine liver metastases: a tumor-specific analysis with dose estimation using SPECT-CT","volume":"28","author":"Chansanti","year":"2017","journal-title":"J\u00a0Vasc Intervent Radiol"},{"key":"10.1016\/j.hpb.2018.12.014_bib28","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/jgh.13752","article-title":"Single-institution experience of radioembolization with yttrium-90 microspheres for unresectable metastatic neuroendocrine liver tumors","volume":"32","author":"Jia","year":"2017","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.hpb.2018.12.014_bib29","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1007\/s00330-017-4856-2","article-title":"Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model","volume":"27","author":"Do Minh","year":"2017","journal-title":"Eur Radiol"},{"key":"10.1016\/j.hpb.2018.12.014_bib30","doi-asserted-by":"crossref","first-page":"860","DOI":"10.21037\/jgo.2016.08.04","article-title":"Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study","volume":"7","author":"Fidelman","year":"2016","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.hpb.2018.12.014_bib31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cct.2016.08.001","article-title":"Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization","volume":"50","author":"Fan","year":"2016","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.hpb.2018.12.014_bib32","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00259-015-3264-6","article-title":"Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases","volume":"43","author":"Barbier","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.hpb.2018.12.014_bib33","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5152\/dir.2014.14036","article-title":"Radioembolization with yttrium-90 resin microspheres for neuroendocrine tumor liver metastases","volume":"21","author":"Peker","year":"2015","journal-title":"Diagn Interv Radiol"},{"key":"10.1016\/j.hpb.2018.12.014_bib34","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1016\/j.ejca.2013.05.012","article-title":"Radioembolisation for liver metastases: results from a prospective 151 patient multi-institutional phase II study","volume":"49","author":"Benson","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.hpb.2018.12.014_bib35","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2967\/jnumed.112.107482","article-title":"90Y radioembolization after radiation exposure from peptide receptor radionuclide therapy","volume":"53","author":"Ezziddin","year":"2012","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.hpb.2018.12.014_bib36","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1477-2574.2011.00405.x","article-title":"Predictors of response to radio-embolization (TheraSphere\u00ae) treatment of neuroendocrine liver metastasis","volume":"14","author":"Shaheen","year":"2012","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.hpb.2018.12.014_bib37","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.ijrobp.2011.07.041","article-title":"Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes","volume":"83","author":"Memon","year":"2012","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.hpb.2018.12.014_bib38","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s00270-011-0248-1","article-title":"Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres","volume":"35","author":"Paprottka","year":"2012","journal-title":"Cardiovasc Interv Radiol"},{"key":"10.1016\/j.hpb.2018.12.014_bib39","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2298\/VSP1104341A","article-title":"Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for hepatic neuroendocrine metastases: initial experience at a single center","volume":"68","author":"Arslan","year":"2011","journal-title":"Vojnosanit Pregl"},{"key":"10.1016\/j.hpb.2018.12.014_bib40","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2010-0292","article-title":"Transarterial chemoembolization and selective internal radiation for the treatment of patients with metastatic neuroendocrine tumors: a comparison of efficacy and cost","volume":"16","author":"Whitney","year":"2011","journal-title":"Oncol"},{"key":"10.1016\/j.hpb.2018.12.014_bib41","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1097\/SLA.0b013e3181d3d24a","article-title":"Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases","volume":"251","author":"Saxena","year":"2010","journal-title":"Ann Surg"},{"key":"10.1016\/j.hpb.2018.12.014_bib42","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/bjs.6931","article-title":"Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases","volume":"97","author":"Cao","year":"2010","journal-title":"Br J Surg"},{"key":"10.1016\/j.hpb.2018.12.014_bib43","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/cncr.23685","article-title":"Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases","volume":"113","author":"King","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.hpb.2018.12.014_bib44","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/SLA.0b013e3181728a45","article-title":"90Y Radioembolization for metastatic neuroendocrine liver tumors","volume":"247","author":"Rhee","year":"2008","journal-title":"Ann Surg"},{"key":"10.1016\/j.hpb.2018.12.014_bib45","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jvir.2007.09.006","article-title":"Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization","volume":"19","author":"Murthy","year":"2008","journal-title":"J\u00a0Vasc Intervent Radiol"},{"key":"10.1016\/j.hpb.2018.12.014_bib46","first-page":"631","article-title":"Intra-arterial treatment with 90 yttrium microspheres in treatment-refractory and unresectable liver metastases of neuroendocrine tumors and the use of 111 in-octreotide scintigraphy in the evaluation of treatment response","volume":"26","author":"Lacin","year":"2011","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.hpb.2018.12.014_bib47","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/MPA.0b013e31825f4087","article-title":"Radioembolization for treatment of liver metastases from neuroendocrine tumors: correlation with imaging and biomarkers","volume":"42","author":"Ozao-Choy","year":"2013","journal-title":"Pancreas"},{"key":"10.1016\/j.hpb.2018.12.014_bib48","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000209849","article-title":"Selective internal radiotherapy with yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study","volume":"79","author":"Kalinowski","year":"2009","journal-title":"Digestion"},{"key":"10.1016\/j.hpb.2018.12.014_bib49","doi-asserted-by":"crossref","first-page":"441","DOI":"10.21037\/jgo.2016.02.02","article-title":"Ki67 score as a potential predictor in the selection of liver-directed therapies for metastatic neuroendocrine tumors: a single institutional experience","volume":"7","author":"Singla","year":"2016","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.hpb.2018.12.014_bib50","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00270-016-1478-z","article-title":"Embolotherapy for neuroendocrine tumor liver metastases: prognostic factors for hepatic progression-free survival and overall survival","volume":"40","author":"Chen","year":"2017","journal-title":"Cardiovasc Interv Radiol"},{"key":"10.1016\/j.hpb.2018.12.014_bib51","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00270-016-1323-4","article-title":"Lung shunt fraction prior to yttrium-90 radioembolization predicts survival in patients with neuroendocrine liver metastases: single-center prospective analysis","volume":"39","author":"Ludwig","year":"2016","journal-title":"Cardiovasc Interv Radiol"},{"key":"10.1016\/j.hpb.2018.12.014_bib52","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/hep.29691","article-title":"Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience","volume":"68","author":"Salem","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.hpb.2018.12.014_bib53","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1245\/s10434-014-4164-x","article-title":"Is yttrium-90 radioembolization a viable treatment option for unresectable, chemorefractory colorectal cancer liver metastases? A large single-center experience of 302 patients","volume":"22","author":"Saxena","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.hpb.2018.12.014_bib54","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40336-016-0172-0","article-title":"The role of 90Y-radioembolization in downstaging primary and secondary hepatic malignancies: a systematic review","volume":"4","author":"Braat","year":"2016","journal-title":"Clin Transl imaging"},{"key":"10.1016\/j.hpb.2018.12.014_bib55","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1148\/radiol.2018171768","article-title":"Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma","volume":"287","author":"Lewandowski","year":"2018","journal-title":"Radiology"},{"key":"10.1016\/j.hpb.2018.12.014_bib56","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jss.2009.05.021","article-title":"Safety of hepatic resection in metastatic disease to the liver after yttrium-90 therapy","volume":"166","author":"Whitney","year":"2011","journal-title":"J\u00a0Surg Res"},{"key":"10.1016\/j.hpb.2018.12.014_bib57","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.2967\/jnumed.113.135855","article-title":"The efficacy of hepatic 90Y resin radioembolization for metastatic neuroendocrine tumors: a meta-analysis","volume":"55","author":"Devcic","year":"2014","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.hpb.2018.12.014_bib58","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.jvir.2017.05.011","article-title":"Long-term hepatotoxicity of yttrium-90 radioembolization as treatment of metastatic neuroendocrine tumor to the liver","volume":"28","author":"Su","year":"2017","journal-title":"J\u00a0Vasc Intervent Radiol"},{"key":"10.1016\/j.hpb.2018.12.014_bib59","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejrad.2018.01.012","article-title":"Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: a systematic review","volume":"100","author":"Jia","year":"2018","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.hpb.2018.12.014_bib60","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hpb.2018.12.014_bib61","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1097\/SLA.0b013e3181fd37e8","article-title":"The impact of 68Ga-DOTATOC positron emission tomography\/computed tomography on the multimodal management of patients with neuroendocrine tumors","volume":"252","author":"Frilling","year":"2010","journal-title":"Ann Surg"},{"key":"10.1016\/j.hpb.2018.12.014_bib62","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/cncr.31192","article-title":"Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases","volume":"124","author":"Kim","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.hpb.2018.12.014_bib63","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/bjs.6468","article-title":"Treatment of liver metastases in relation to the extent of hepatic disease","volume":"96","author":"Frilling","year":"2009","journal-title":"Br J Surg"}],"container-title":["HPB"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1365182X19300243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1365182X19300243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:20:45Z","timestamp":1761265245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1365182X19300243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":63,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1365182X19300243"],"URL":"https:\/\/doi.org\/10.1016\/j.hpb.2018.12.014","relation":{},"ISSN":["1365-182X"],"issn-type":[{"value":"1365-182X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radioembolisation with 90Y microspheres for neuroendocrine liver metastases: an institutional case series, systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"HPB","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hpb.2018.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}